Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Payables: 2020-2025

Historic Payables for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $6.5 million.

  • Xeris Biopharma Holdings' Payables fell 12.40% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year decrease of 22.81%. This contributed to the annual value of $2.3 million for FY2024, which is 80.20% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Payables stood at $6.5 million for Q3 2025, which was down 31.02% from $9.5 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Payables high stood at $12.1 million for Q3 2023, and its period low was $2.3 million during Q4 2024.
  • Moreover, its 3-year median value for Payables was $7.5 million (2024), whereas its average is $8.4 million.
  • Its Payables has fluctuated over the past 5 years, first spiked by 208.43% in 2023, then slumped by 80.20% in 2024.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Payables stood at $8.9 million in 2021, then plummeted by 48.39% to $4.6 million in 2022, then surged by 151.09% to $11.6 million in 2023, then slumped by 80.20% to $2.3 million in 2024, then fell by 12.40% to $6.5 million in 2025.
  • Its Payables stands at $6.5 million for Q3 2025, versus $9.5 million for Q2 2025 and $6.4 million for Q1 2025.